EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic Cerebrospinal Fluid Biomarkers in Traumatic Brain Injury: An Evolving Frontier

Bibha Osti, Md Moshiur Rahman

Indian Journal of Neurotrauma · 01.12.2025 · 22 (02) · 208-210

DOI: 10.1055/s-0045-1809657 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Neurotrauma, erschienen am 01.12.2025. Verfasst von Bibha Osti und 1 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Traumatic brain injury (TBI) remains a life-threatening concern worldwide, contributing to long-term disability and mortality. Identifying reliable prognostic biomarkers is essential for tailoring therapeutic strategies and predicting outcomes. Among various biological matrices, cerebrospinal fluid (CSF) holds promise due to its proximity to the site of injury and direct reflection of central nervous system pathology. This letter concisely overviews the most studied CSF-based prognostic biomarkers in TBI and highlights their clinical implications. Neuronal injury markers are among the most extensively studied. Neuron-specific enolase (NSE) is released from damaged neurons, and elevated CSF levels are correlated with poor Glasgow Outcome Scores and mortality, particularly in severe TBI cases.[ 1 ] Similarly, S100B, a calcium-binding protein from astrocytes, has shown predictive value in both acute and subacute phases of injury, especially when combined with radiological and clinical parameters.[ 2 ] [ 3 ] Neurofilament light chain (NFL), indicative of axonal damage, has recently gained attention for its role in predicting long-term neurocognitive deficits.[ 4 ] Tau protein and its phosphorylated form, commonly studied in Alzheimer's disease, have also been detected at elevated levels in TBI, especially in patients progressing toward posttraumatic dementia.[ 5 ] Inflammatory biomarkers such as interleukin (IL)-6, IL-8, and IL-1β and tumor necrosis factor-alpha are consistently elevated in severe TBI and are strongly associated with secondary injury cascades, including cerebral edema and increased intracranial pressure.[ 6 ] [ 7 ] The chemokine monocyte chemoattractant protein-1 (MCP-1) is derived from the blood–brain barrier (BBB) and has worse functional outcomes.[ 8 ] From a vascular and metabolic standpoint, the albumin quotient (CSF/serum ratio) is a marker of BBB integrity and is frequently deranged in severe TBI, correlating with cerebral autoregulatory dysfunction.[ 9 ] Furthermore, matrix metalloproteinase-9, a protease involved in extracellular matrix remodeling, has been implicated in BBB disruption and neuroinflammation, and its presence in CSF predicts the development of intracranial hypertension.[ 10 ] Metabolic markers such as lactate/pyruvate ratios and glutamate concentrations help detect mitochondrial dysfunction and excitotoxicity. Elevated CSF glutamate, for instance, is associated with poor neurological recovery.[ 11 ] Oxidative stress markers, including F2-isoprostanes, have also shown promise in indicating lipid peroxidation and neuronal injury severity.[ 12 ] The application of CSF biomarkers in TBI is increasingly being explored to assist in early diagnosis, therapeutic decision-making, and prognostic evaluation. Biomarkers such as glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1) have demonstrated utility in identifying neuronal and astrocytic damage, respectively, particularly in moderate-to-severe injuries.[ 13 ] Inflammatory mediators, including IL-6 and high-mobility group box 1 (HMGB1), have shown potential in detecting early secondary injury responses and BBB disruption, guiding targeted interventions.[ 14 ] Moreover, combining biomarkers into multiplex platforms enhances their predictive value. It may be particularly effective when integrated with neuroimaging and clinical scales like the Glasgow Coma Scale or Rotterdam CT score.[ 15 ] From a prognostic perspective, elevated CSF levels of GFAP, UCH-L1, and spectrin breakdown products are significantly associated with long-term neurological deficits and increased mortality rates.[ 16 ] Additionally, metabolic derangements reflected by abnormal CSF lactate and glutamate concentrations point toward mitochondrial dysfunction and excitotoxicity, mechanisms closely tied to poor recovery trajectories.[ 17 ] Implementing these biomarkers in acute clinical workflows may facilitate early prognostication, inform family counseling, and optimize patient selection for neuroprotective trials or rehabilitative strategies to improve functional outcomes. We outlined a table with key TBI CSF biomarkers with optimal detection timing ([ Table 1 ]). Table 1 Key cerebrospinal fluid (CSF) biomarkers in traumatic brain injury with timing of optimal detection Biomarker Source or function Clinical use Suggested time frame for CSF sampling Neuron-specific enolase (NSE) Released from injured neurons Associated with neuronal damage and poor outcomes 6–24 hours post-injury S100B Derived from astrocytes Aids in early diagnosis and severity assessment Within first 48 hours Neurofilament light chain (NFL) Reflects axonal breakdown Predicts long-term neurological impairment Several days to weeks Tau/phosphorylated tau Microtubule-associated neuronal protein Linked to chronic degeneration and cognitive decline 3 days to several weeks Interleukin-6 (IL-6) Pro-inflammatory cytokine Marker of acute neuroinflammatory response 6–72 hours TNF-α, IL-1β, IL-8 Cytokines involved in immune signaling Indicate ongoing inflammation and edema risk 12–72 hours Monocyte chemoattractant protein-1 (MCP-1) Chemokine from glial cells Suggests blood–brain barrier disruption First 72 hours Matrix metalloproteinase-9 (MMP-9) Enzyme affecting vascular permeability Linked to edema and rising intracranial pressure 1–4 days Lactate/pyruvate ratio Reflects metabolic stress in brain cells Indicates mitochondrial dysfunction 12–48 hours Glutamate Excitatory neurotransmitter Marker of excitotoxic injury Within 12–48 hours F2-isoprostanes Byproduct of lipid oxidation Marker of oxidative injury severity 2–3 days While many of these biomarkers remain under investigation, several—especially S100B, NSE, and NFL—are nearing clinical applicability, particularly when used in multimodal panels. However, challenges remain in standardizing measurement, timing of collection, and establishing reference ranges. In conclusion, CSF biomarkers offer a valuable window into the pathophysiological processes of TBI and hold substantial prognostic potential. Future studies should focus on longitudinal profiling, integration with imaging and electrophysiological tools, and developing validated biomarker panels for routine clinical use. Publication History Article published online: 13 June 2025 © 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

Zitieren

APA

Osti, B., & Rahman, M. M. (2025). Prognostic Cerebrospinal Fluid Biomarkers in Traumatic Brain Injury: An Evolving Frontier. Indian Journal of Neurotrauma, 22(02), 208-210. https://doi.org/10.1055/s-0045-1809657

Vancouver

Osti B, Rahman MM. Prognostic Cerebrospinal Fluid Biomarkers in Traumatic Brain Injury: An Evolving Frontier. Indian Journal of Neurotrauma. 2025;22(02):208-210. doi:10.1055/s-0045-1809657

BibTeX
@article{Osti2025,
  author = {Osti, Bibha and Rahman, Md Moshiur},
  title = {Prognostic Cerebrospinal Fluid Biomarkers in Traumatic Brain Injury: An Evolving Frontier},
  journal = {Indian Journal of Neurotrauma},
  year = {2025},
  volume = {22},
  number = {02},
  pages = {208--210},
  doi = {10.1055/s-0045-1809657}
}
Kostenlos starten →